Phase 3, Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Newly Diagnosed Multiple Myeloma (NDMM), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP)
### Instruction:
Identify the study with the following condition. 
### Input:
Phase 3, Daratumumab+Velcade (Bortezomib) +Melphalan+Prednisone (D-VMP), Newly Diagnosed Multiple Myeloma (NDMM), Anti-CD38 MAb, Velcade (Bortezomib) +Melphalan+Prednisone (VMP) 
### Output:
Popular Name is ALCYONE, Study ID is NCT02195479